| IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed |
AUSTIN, Texas--(BUSINESS WIRE)---- $AMD #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENSai™ platform, with a direct comparison to gold-standard wet-lab methods. The results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and cos. |
businesswire.com |
2025-05-12 12:01:00 |
Czytaj oryginał (ang.) |
| Fujifilm Invites Entries for its Innovation Print Awards Contest |
HANOVER PARK, Ill.--(BUSINESS WIRE)--FUJIFILM North America Corporation, Business Innovation Division, has announced a call for entries to Fujifilm's global Innovation Print Awards (IPA) contest. The IPA contest, designed to highlight and celebrate creative print projects printed using Fujifilm's wide array of press solutions, is open to Fujifilm press owners across the globe. “Fujifilm print service providers across the globe create incredible projects on a daily basis,” said Yuji Oki, general. |
businesswire.com |
2025-05-05 14:00:00 |
Czytaj oryginał (ang.) |
| 10 Barrel Brewing Launches Non-Alcoholic Apocalypse IPA, a Bold Craft Brew for Your Next Adventure |
BEND, Ore., April 30, 2025 (GLOBE NEWSWIRE) -- 10 Barrel Brewing, a Tilray Brands, Inc., (NASDAQ: TLRY and TSX: TLRY) craft beer brand, is excited to announce the launch of NA Apocalypse IPA, a non-alcoholic version of their beloved Apocalypse IPA . This new offering delivers the same bold, hop-driven flavor that fans have come to love, now without the alcohol. |
globenewswire.com |
2025-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods |
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration's (FDA) recent decision to phase out animal testing requirements for monoclonal antibodies and other pharmaceutical products. The FDA's announcement marks a significant advancement in regulatory modernization and aligns fully with ImmunoPrecise's mission to revolutionize drug discovery and developmen. |
businesswire.com |
2025-04-11 12:40:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies (IPA) Upgraded to Buy: What Does It Mean for the Stock? |
ImmunoPrecise Antibodies (IPA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-04-03 17:05:57 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript |
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q3 2025 Earnings Conference Call March 28, 2025 10:30 AM ET Company Participants Jennifer Bath - Chief Executive Officer and President Joseph Scheffler - Interim Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. |
seekingalpha.com |
2025-03-28 14:59:05 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates |
ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. |
zacks.com |
2025-03-28 12:15:34 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 |
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter (“Q3”) of its 2025 fiscal year (“FY25”), which ended January 31, 2025. "As we continue to revolutionize the AI-enabled drug discovery sector, our recent milestones underscore the growing recognition of our innovative AI and growth potential. Notably, we've secured a strategic part. |
businesswire.com |
2025-03-28 10:01:00 |
Czytaj oryginał (ang.) |
| SweetWater Brewing Company and Georgia Aquarium Celebrate Third Year of Partnership with Limited Edition Aquarium-Themed Can Art for OG IPA |
ATLANTA, March 20, 2025 (GLOBE NEWSWIRE) -- SweetWater Brewing Company ("SweetWater Brewing" or "SweetWater"), the largest craft brewer in Georgia and the Southeast and a Tilray Brands, Inc., company (NASDAQ: TLRY and TSX: TLRY), announces the third year of its partnership with Georgia Aquarium by releasing a limited-edition aquarium-themed version of SweetWater's OG IPA. This collaboration highlights the shared commitment of both organizations to environmental conservation and community engagement. |
globenewswire.com |
2025-03-20 09:00:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. |
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) is pleased to announce a strategic partnership with a leading biotechnology company with a multi-billion-dollar market capitalization to advance the discovery and development of Antibody-Drug Conjugates (ADCs) and bispecific antibodies for the treatment of cancer. This collaboration focuses on leveraging contract research expertise while integrating IPA's proprietary B-cell Select™ platform and artificial intellig. |
businesswire.com |
2025-03-13 09:02:00 |
Czytaj oryginał (ang.) |
| IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 |
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its aud. |
businesswire.com |
2025-03-12 00:17:00 |
Czytaj oryginał (ang.) |
| IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025 |
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2025, on Thursday, March 13, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference. |
businesswire.com |
2025-03-05 10:01:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies Announces Key Leadership Changes |
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). Additionally, IPA announces the planned departure of Chris Buyse from the Board of Directors. Kamil Isaev Joins IPA's Board of Directors IPA is pleased to welcome D. |
businesswire.com |
2025-02-24 10:01:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period |
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced that its application to transfer its securities to the Nasdaq Capital Market has been approved by Nasdaq Listing Qualifications. This transition allows IPA an additional 180-day compliance period, until August 18, 2025, to meet the minimum bid price requirement of $1.00 per share. The Company's common stock will t. |
businesswire.com |
2025-02-20 10:01:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture |
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (“IPA” or the “Company”) (NASDAQ: IPA), a leader in AI-driven antibody discovery and development, today announced the successful completion of its previously disclosed USD $8.8 million “at-the-market” equity offering program (the “ATM Program”) alongside the full conversion of its outstanding debenture with Yorkville Advisors, significantly enhancing the Company's capital structure. Strategic ATM Offering Raises USD $7.0 Million Util. |
businesswire.com |
2025-01-27 10:01:00 |
Czytaj oryginał (ang.) |
| IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment |
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction in diabetes treatment. These AI-designed therapeutics aim to improve upon current GLP-1 therapies, which are widely used for managing type 2 diabetes and obesity. Created using the Company's proprietary LENSai™ platform, an AI-driven system that an. |
businesswire.com |
2025-01-22 09:02:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation |
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced artificial intelligence with first-principles thinking, the BioStrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency. Traditional drug discovery often builds on outdated frameworks, layering new tools onto existin. |
businesswire.com |
2025-01-17 10:01:00 |
Czytaj oryginał (ang.) |
| Lighten Up! Dogfish Head Flips the Script on New Year's Resolutions, Celebrates New 30 Minute Light IPA on “Quitter's Day” with Beer Money & Other Rewards |
In honor of its newest beer, brewery to celebrate “Quitter's Day” and reward drinkers who throw in the towel on their New Year's resolutions early with beer money and medals In honor of its newest beer, brewery to celebrate “Quitter's Day” and reward drinkers who throw in the towel on their New Year's resolutions early with beer money and medals |
globenewswire.com |
2025-01-08 12:24:00 |
Czytaj oryginał (ang.) |
| Samuel Adams Offers Two Dry January Tips: Try Just The Haze IPA and Don't Waste Great Beer |
Boston, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Samuel Adams, America's #1 most trusted craft beer brand, is offering two simple tips to Dry January participants on how to make it to the finish line: |
globenewswire.com |
2025-01-07 10:25:00 |
Czytaj oryginał (ang.) |
| IPA Announces Resignation of Chief Financial Officer |
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time. “Kristin has been a valued member of our team over this past year," said Dr. Jennifer Bath, IPA's President and Chief Executive Officer. ". |
businesswire.com |
2024-12-31 21:56:00 |
Czytaj oryginał (ang.) |
| $116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors |
SANTA MARIA, Calif.--(BUSINESS WIRE)-- #apartmentinvestments--$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors. |
businesswire.com |
2024-12-31 00:03:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases |
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce significant insider activity, with key members of its executive team and subsidiary co-founders demonstrating confidence in the Company's strategic direction and long-term potential through substantial share purchases. Over the past week, CEO Dr. Jennifer Bath and BioStrand co-founders Dirk Va. |
businesswire.com |
2024-12-23 10:30:00 |
Czytaj oryginał (ang.) |
| IPA to Present at The Microcap Conference 2025 |
VICTORIA, BC / ACCESSWIRE / December 19, 2024 / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. |
accesswire.com |
2024-12-19 12:15:00 |
Czytaj oryginał (ang.) |
| IPA to Present at The Microcap Conference 2025 |
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, in Atlantic City, NJ. IPA's management team will deliver a corporate presentation and engage in one-on-one meetin. |
businesswire.com |
2024-12-19 10:00:00 |
Czytaj oryginał (ang.) |
| QIAGEN Stock Gains Following the Latest Launch of IPA Interpret |
QGEN announces the launch of IPA Interpret to extend the analysis capabilities of a human-curated knowledge base with AI technology. |
zacks.com |
2024-12-13 11:06:07 |
Czytaj oryginał (ang.) |
| QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data |
REDWOOD CITY, Calif. & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. Leveraging AI technology, IPA Interpret helps distill complex differential expression analyses into actionable insights, helping researchers understand which genes are involved in a disease, a biological process o. |
businesswire.com |
2024-12-12 18:05:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call Transcript |
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q2 2025 Earnings Conference Call December 10, 2024 10:30 AM ET Company Participants Jennifer Bath - CEO Kristin Taylor - CFO Conference Call Participants Swayampakula Ramakanth - H.C. |
seekingalpha.com |
2024-12-10 19:33:09 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies Ltd. (IPA) Reports Q2 Loss, Misses Revenue Estimates |
ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. |
zacks.com |
2024-12-10 12:45:25 |
Czytaj oryginał (ang.) |
| IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference |
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced it will be presenting at The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024, at the New York Athletic Club in New York City. The conference offers emerging growth, and dynamic publicly traded companies access to institutional and ind. |
businesswire.com |
2024-12-04 10:00:00 |
Czytaj oryginał (ang.) |
| IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024 |
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2025, on Tuesday, December 10, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will ho. |
businesswire.com |
2024-12-03 10:30:00 |
Czytaj oryginał (ang.) |
| $20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies |
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to announce a significant breakthrough in its primary cancer research initiatives. This accomplishment not only highlights IPA's cutting-edge discovery and AI capabilities, but it also strategically places the company in the rapidly growing market for these cancer-combating antibodies, which is projected to reach $20.7 billion by 2. |
businesswire.com |
2024-11-13 11:00:00 |
Czytaj oryginał (ang.) |
| voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS) |
FRIEDBERG, Germany--(BUSINESS WIRE)--voxeljet AG (OTCMKTS: VJTTY) (the ‘Company', ‘voxeljet', or ‘we'), a provider of high-speed, large-format 3D printers and on-demand parts services to industrial and commercial customers, Dressler Group GmbH, and Fraunhofer IPA today announced the successful completion of a material study for waste PA12 powder from laser-based 3D printing systems. In the study, waste powder from Selective Laser Sintering systems was successfully recycled by Dressler Group and. |
businesswire.com |
2024-11-13 10:00:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation |
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPA's latest advancements in AI-driven design, biologics innovation, and strategic technological developments. Highlights of TECHDAY: Prese. |
businesswire.com |
2024-11-04 10:01:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology |
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces its significant contribution to a groundbreaking study. The research, led by top scientists at the Mayo Clinic, was initially published in bioRxiv and subsequently peer-reviewed and published in the prestigious journal Autophagy. Titled "Development and Characterization of Phospho-Ubiquitin Antibodies to Monitor. |
businesswire.com |
2024-10-28 09:30:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024 |
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation at BioStrand, IPA's AI subsidiary, will participate on a Fireside Chat during the AI Driven Drug Discovery Summit USA 2024 taking place at the Aloft Boston Seaport District Hotel, Boston, Massachusetts, November 12-14, 2024. AI Driven Drug Discovery Summit Date:. |
businesswire.com |
2024-10-21 13:00:00 |
Czytaj oryginał (ang.) |
| Institutional Property Advisors Brokers $92.5 Million Multifamily Sale in L.A.'s NoHo Arts District |
LOS ANGELES--(BUSINESS WIRE)-- #apartmentbrokers--Institutional Property Advisors Brokers $92.5 Million Multifamily Sale in L.A.'s NoHo Arts District. |
businesswire.com |
2024-10-16 18:54:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments |
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today proudly announces the clinical progress achieved with rabbit monoclonal antibodies designed and developed using IPA's proprietary B Cell Select® platform for the clinical-stage company, OncoResponse Inc. This achievement underscores IPA's leadersh. |
businesswire.com |
2024-09-26 13:00:00 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies Ltd. (IPA) Q1 2025 Earnings Call Transcript |
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q1 2025 Earnings Conference Call September 16, 2024 10:30 AM ET Company Participants Jennifer Bath - CEO Kristin Taylor - CFO Conference Call Participants Swayampakula Ramakanth - H.C. |
seekingalpha.com |
2024-09-16 17:46:05 |
Czytaj oryginał (ang.) |
| ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Misses Revenue Estimates |
ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.09. |
zacks.com |
2024-09-16 15:26:13 |
Czytaj oryginał (ang.) |